跳至主要内容
临床试验/NCT05371483
NCT05371483Enrolling By Invitation不适用

Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments

Mayo Clinic2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年5月18日最近更新:
适应症

试验速览

阶段
不适用
状态
Enrolling By Invitation
发起方
Mayo Clinic
入组人数
100
试验地点
2
主要终点
Change in mean 24-hour ambulatory blood pressure

研究概览

简要总结

This is an observational study evaluating patients diagnosed with narcolepsy or idiopathic hypersomnia that have been prescribed a new/different hypersomnia treatment. The study is being done to better understand how hypersomnia treatment(s) impact blood pressure and cognitive function.

详细描述

This is an observational study evaluating how hypersomnia medications influence blood pressure and cognitive function in patients diagnosed with narcolepsy or idiopathic hypersomnia. Blood pressure will be assessed using 24-hour ambulatory blood pressure monitoring equipment. Cognitive function will be evaluated using the Oculo-Cognitive Addition Test (OCAT). Both tests will performed at baseline (e.g., before starting a new hypersomnia medication) and after taking a stable dose of the new hypersomnia medication for at least three months. All medications will be prescribed by a clinical sleep specialist as part of routine medical care and covered by subject's health insurance plan (i.e., no medications are dispensed/titrated/paid for by the study investigators/trial).

The 24-hour ambulatory blood pressure test will be setup in person by staff. During the blood pressure test, the study participant will also complete a sleep diary and wear an actigraphy watch to track activity and sleep-wake cycle. The 24-hour ambulatory blood pressure test will be programmed to inflate a blood pressure cuff placed around the arm every 15 - 30 minutes.

The OCAT test, which takes approximately 15-20 minutes to complete, will be completed in person as well.

Each study participant may complete one or both tests. Each study participant may complete more than two assessments (e.g., patient that has been prescribed a second hypersomnia medication). If a patient presents already taking a medication of interest at baseline for at least the last 3 months then the participant may undergo baseline assessment(s) while taking respective medication(s).

研究设计

研究类型
Observational
观察模型
Case Crossover
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with narcolepsy or idiopathic hypersomnia according to International Classification of Sleep Disorders, third edition
  • Age 18 - 75 years
  • BMI between 18 and 40 kg/m2
  • Prescribed a medication of interest (e.g., sodium oxybate, low sodium oxybate, pitolisant, modafinil/armodafinil, solriamfetol, traditional stimulant(s)) by a clinical sleep specialist as part of routine medical care.
  • Subject must be willing to postpone starting medication until after completion of baseline assessment(s).
  • If subject has been taking a prescribed hypersomnia medication(s) at a stable dose for at least 3 months and has been prescribed a new medication, then subject may complete baseline assessment(s) while taking initial hypersomnia medication(s) before starting new medication.

排除标准

  • Any change to medication(s) within the last 45 days
  • History of chronic alcohol or drug abuse within the prior 12 months
  • Heart failure, history of severe hypertension, or other cardiovascular disease compromising the patient's wellbeing or ability to participate in this study
  • Use of any sleep apnea treatment (e.g., Positive Airway Pressure (PAP) therapy, oral appliance therapy, etc.) within 45 days of baseline assessment visit
  • Participation in another study of an investigational drug within the 28 days prior to screening visit or currently
  • Pregnancy and/or breast-feeding
  • Subjects who, in the opinion of the Investigator, may not be suitable for the study.

结局指标

主要结局

Change in mean 24-hour ambulatory blood pressure

时间窗: Baseline, at least 3 months

Change in 24-hour ambulatory blood pressure from baseline (pre-treatment) to after taking a stable dose of medication for at least 3 months

次要结局

  • Change in Oculo-Cognitive Addition Test (OCAT) completion time(Baseline, at least 3 months)
  • Change in mean daytime and nighttime 24-hour ambulatory blood pressure(Baseline, at least 3 months)
  • Change in 24-hour ambulatory blood pressure diurnal pattern (dipper versus non-dipper)(Baseline, at least 3 months)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Chad M. Ruoff

Principal Investigator

Mayo Clinic

研究点 (2)

Loading locations...

相似试验